Trials / Completed
CompletedNCT06454032
Effect of 12-week FW Programme on Sex Hormone Levels and Risk Factors for MS in Postmenopausal Women
Effect of 12-week Fitness Walking Programme on Sex Hormone Levels and Risk Factors for Metabolic Syndrome in Postmenopausal Women
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Beijing Sport University · Academic / Other
- Sex
- Female
- Age
- 50 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
Postmenopausal women were separated into two groups: one participating in a 12-week fitness walking programe as the fitness walking group, and the other maintaining their regular lifestyle as the control group. The study evaluated alterations in health markers and examined the correlation between metabolic syndrome risk factors and sex hormone levels before and after the intervention.
Detailed description
According to the inclusion and exclusion criteria, our study invlved postmenopausal women aged from 50 to 69 years old. After the selection process, baseline assessments were conducted, including evaluations of metabolic syndrome risk factors, body morphology measurements, sex hormone levels, and cardiopulmonary exercise testing. Participants were then randomly assigned to either the fitness walking group or the control group using a random number table. Participants in the fitness walking group completed a 12-week fitness walking program, while those in the control group maintained their usual lifestyle without any intervention. During the post-intervention assessment, all baseline measurements were repeated to evaluate changes in the previously measured indicators.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Fitness walking | Fitness walking for 12 weeks. |
| BEHAVIORAL | Maintained lifestyle | Maintained their normal lifestyle, without exercise intervention. |
Timeline
- Start date
- 2022-04-16
- Primary completion
- 2022-09-30
- Completion
- 2022-12-30
- First posted
- 2024-06-12
- Last updated
- 2024-06-12
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06454032. Inclusion in this directory is not an endorsement.